Int J Stem Cells.  2024 Nov;17(4):407-417. 10.15283/ijsc24089.

Efficient Treatment of Psoriasis Using Conditioned Media from Mesenchymal Stem Cell Spheroids Cultured to Produce Transforming Growth Factor-β1-Enriched Small-Sized Extracellular Vesicles

• Song M
• Lim KM
• Song K
• Kang GH
• Kim SJ
• Lee Y
• Yu S
• Jeong KH
• Cho SG

• KMID: 2562360
• DOI: http://doi.org/10.15283/ijsc24089

Abstract

Psoriasis is a common chronic inflammatory disease in which keratinocytes proliferate abnormally due to excessive immune action. Psoriasis can be associated with various comorbidities and has a significant impact on health-related quality of life. Although many systemic treatments, including biologic agents, have been developed, topical treatment remains the main option for psoriasis management. Consequently, there is an urgent need to develop topical treatments with minimal side effects and high efficacy. Mesenchymal stem cells (MSCs) exhibit excellent immune regulation, anti-inflammatory activities, and therapeutic effects, and MSC-derived extracellular vesicles (EVs) can serve as crucial mediators of functional transfer from MSCs. Therefore, this study aimed to develop a safe and easy-to-use emulsion cream for treating psoriasis using MSC conditioned media (CM) containing EVs. We developed an enhanced Wharton’s jelly MSC (WJ-MSC) culture method through a three-dimensional (3D) culture containing exogenous transforming growth factor-β3. Using the 3D culture system, we obtained CM from WJ-MSCs, which yielded a higher EV production compared to that of conventional WJ-MSC culture methods, and investigated the effect of EV-enriched 3D-WJMSC-CM cream on psoriasis-related inflammation. Administration of the EV-enriched 3D-WJ-MSC-CM cream significantly reduced erythema, thickness, and scaling of skin lesions, alleviated imiquimod-induced psoriasiform lesions in mice, and ameliorated histopathological changes in mouse skin. The upregulated mRNA expression of inflammatory cytokines, including IL-17a, IL-22, IL-23, and IL-36, decreased in the lesions. In conclusion, we present here a new topical treatment for psoriasis using an MSC EV-enriched cream.

Keyword

Psoriasis; Extracellular vesicles; Mesenchymal stem cells; Emulsions; Immunomodulation

Figure

• 

  Fig. 1 Schematic diagram of the topical treatment. (A) Differences in the 2D and 3D culture methods, as well as the advantages of MSCs and 3D MSCs. The arrow represents the shaking motion applied to the culture medium within the culture flask. (B) Schedule of the cream processing and experimental procedures. IMQ was topically applied from days 0∼6, and MSC conditioned media cream applied from days 8∼10. The experiment was terminated on day 12. 2D: two-dimensional, WJ: Wharton’s jelly, CM: conditioned media, 3D: three-dimensional, MSCs: mesenchymal stem cells, IMQ: imiquimod.

• 

  Fig. 2 Characterization of WJ-MSCs and their CM. (A) Comparative analysis of nanoparticles in 2D-WJ-CM and 3D-WJ-CM. The distribution of nanoparticles by size, total concentration per milliliter, peak size (nm), and median size (nm) were measured using ZetaView (TWIN PMX-220; Particle Metrix). (B) Comparison of protein volume and their EV purity (particle number/protein concentration) in 2D-WJ-CM and 3D-WJ-CM. (C) Total expression of TGF-β1 per 1×109 particles in EVs. TGF-β1 levels were significantly higher in 3D-WJ-CM compared to those in 2D-WJ-CM. (D) Flow cytometry analysis of MSC-positive surface marker CD90/105 and negative surface marker CD45 in 2D-MSCs and 3D-MSCs. 2D: two-dimensional, WJ: Wharton’s jelly, CM: conditioned media, 3D: three-dimensional, MSC: mesenchymal stem cell, EV: extracellular vesicle, TGF-β1: transforming growth factor-β1. Results with a p-value<0.05 were considered statistically significant. **p<0.01, ***p<0.001, ****p<0.0001.

• 

  Fig. 3 Emulsion cream selection. (A) Formulation shape according to oil and emulsifier ratios in 2D-WJ-CM and 3D-WJ-CM. (B) The degree of phase separation according to oil and emulsifier ratios in 2D-WJ-CM and 3D-WJ-CM. The left-angled red line indicates the phase-separated position. (C) Proportion of maintaining the emulsion form. 2D: two-dimensional, WJ: Wharton’s jelly, CM: conditioned media, 3D: three-dimensional.

• 

  Fig. 4 Phenotype of 3D-WJ-CM cream-treated psoriasis-like mice. Mice were randomly divided into five groups: normal, IMQ＋vehicle, IMQ＋MTX, IMQ＋2D-WJ-CM, and IMQ＋3D-WJ-CM groups. (A) Two representative photographs of mice phenotypes before sacrifice. (B) In the back skin of BALB/c mice, the thickness, erythema, and scaling were scored from 0∼4 points from the start of treatment to the date of sacrifice. In addition, the cumulative score combining thickness, erythema, and scaling was presented. Symbols represent the mean standard deviation of six mice. IMQ: imiquimod, MTX: methotrexate, 2D: two-dimensional, WJ: Wharton’s jelly, CM: conditioned media, 3D: three-dimensional. Two-way ANOVA showed significant differences between groups, ###p<0.001, ####p<0.0001 compared to Vehicle and 3D-WJ-CM. *p<0.05, **p<0.01, ***p<0.001 compared to 2D-WJ-CM and 3D-WJ-CM.

• 

  Fig. 5 3D-WJ-CM cream recovery in psoriasis-like mice. (A) H&E staining of mice skin by group. Scale bar=50 μm. (B) Levels of inflammatory cytokines (TLR7, IL-17α, IL-23α, IL-22, and IL-36) in the back skin of psoriasis-like mice treated with 3D-WJ-CM. IMQ: imiquimod, MTX: methotrexate, 2D: two-dimensional, WJ: Wharton’s jelly, CM: conditioned media, 3D: three-dimensional. Results with a p-value<0.05 were considered statistically significant. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, and ns=not significant compared to the IMQ＋vehicle group.

• 

  Fig. 6 3D-WJ-CM attenuates inflammation in vitro. (A) The concentration of nitric oxide in the supernatant of LPS-stimulated RAW 264.7 cells. (B) Protein expression levels of inflammatory cytokines (IL-1β, IL-6, and TNF-α). Protein expression was detected in the cell supernatant by ELISA. LPS: lipopolysaccharide, MTX: methotrexate, 2D: two-dimensional, WJ: Wharton’s jelly, CM: conditioned media, 3D: three-dimensional. ***p<0.001, ****p<0.0001 compared to the LPS group.

Reference

References

1. Wagner EF, Schonthaler HB, Guinea-Viniegra J, Tscha-chler E. 2010; Psoriasis: what we have learned from mouse models. Nat Rev Rheumatol. 6:704–714. DOI: 10.1038/nrrheum.2010.157. PMID: 20877306.

2. Gulliver W. 2008; Long-term prognosis in patients with psoriasis. Br J Dermatol. 159(Suppl 2):2–9. DOI: 10.1111/j.1365-2133.2008.08779.x. PMID: 18700909.

3. Moll JM, Wright V. 1973; Psoriatic arthritis. Semin Arthritis Rheum. 3:55–78. DOI: 10.1016/0049-0172(73)90035-8. PMID: 4581554.

4. Rapp SR, Feldman SR, Exum ML, Fleischer AB Jr, Rebo-ussin DM. 1999; Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol. 41(3 Pt 1):401–407. DOI: 10.1016/S0190-9622(99)70112-X. PMID: 10459113.

5. Gupta MA, Gupta AK. 1998; Depression and suicidal ideation in dermatology patients with acne, alopecia areata, atopic dermatitis and psoriasis. Br J Dermatol. 139:846–850. DOI: 10.1046/j.1365-2133.1998.02511.x. PMID: 9892952.

6. Tyring S, Gottlieb A, Papp K, et al. 2006; Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet. 367:29–35. DOI: 10.1016/S0140-6736(05)67763-X. PMID: 16399150.

7. Lebwohl M, Ting PT, Koo JY. 2005; Psoriasis treatment: traditional therapy. Ann Rheum Dis. 64 Suppl 2(Suppl 2):ii83–ii86. DOI: 10.1136/ard.2004.030791. PMID: 15708945. PMCID: PMC1766882.

8. Toma C, Pittenger MF, Cahill KS, Byrne BJ, Kessler PD. 2002; Human mesenchymal stem cells differentiate to a cardio-myocyte phenotype in the adult murine heart. Circulation. 105:93–98. DOI: 10.1161/hc0102.101442. PMID: 11772882.

9. Baraniak PR, McDevitt TC. 2010; Stem cell paracrine actions and tissue regeneration. Regen Med. 5:121–143. DOI: 10.2217/rme.09.74. PMID: 20017699. PMCID: PMC2833273.

10. Keating A. 2012; Mesenchymal stromal cells: new directions. Cell Stem Cell. 10:709–716. DOI: 10.1016/j.stem.2012.05.015. PMID: 22704511.

11. Li B, Zhang H, Zeng M, et al. 2015; Bone marrow mesenchymal stem cells protect alveolar macrophages from lipopolysac-charide-induced apoptosis partially by inhibiting the Wnt/β-catenin pathway. Cell Biol Int. 39:192–200. DOI: 10.1002/cbin.10359. PMID: 25229877.

12. Paganelli A, Tarentini E, Benassi L, Kaleci S, Magnoni C. 2020; Mesenchymal stem cells for the treatment of psoriasis: a comprehensive review. Clin Exp Dermatol. 45:824–830. DOI: 10.1111/ced.14269. PMID: 32386432.

13. Yang M, Wang L, Chen Z, et al. 2022; Topical administration of the secretome derived from human amniotic epithelial cells ameliorates psoriasis-like skin lesions in mice. Stem Cell Res Ther. 13:393. DOI: 10.1186/s13287-022-03091-9. PMID: 35922852. PMCID: PMC9351215.

14. Yáñez-Mó M, Siljander PR, Andreu Z, et al. 2015; Biological pro-perties of extracellular vesicles and their physiological fun-ctions. J Extracell Vesicles. 4:27066. DOI: 10.3402/jev.v4.27066. PMID: 25979354. PMCID: PMC4433489.

15. Ti D, Hao H, Tong C, et al. 2015; LPS-preconditioned mesenchymal stromal cells modify macrophage polarization for resolution of chronic inflammation via exosome-shuttled let-7b. J Transl Med. 13:308. DOI: 10.1186/s12967-015-0642-6. PMID: 26386558. PMCID: PMC4575470.

16. Sung DK, Chang YS, Sung SI, Ahn SY, Park WS. 2019; Thro-mbin preconditioning of extracellular vesicles derived from mesenchymal stem cells accelerates cutaneous wound healing by boosting their biogenesis and enriching cargo con-tent. J Clin Med. 8:533. DOI: 10.3390/jcm8040533. PMID: 31003433. PMCID: PMC6517934.

17. Lim KM, Han JH, Lee Y, et al. 2022; Rapid production method with increased yield of high-purity extracellular vesicles obtained using extended mitochondrial targeting domain peptide. J Extracell Vesicles. 11:e12274. DOI: 10.1002/jev2.12274. PMID: 36239712. PMCID: PMC9563391.

18. Burnley-Hall N, Willis G, Davis J, Rees DA, James PE. 2017; Nitrite-derived nitric oxide reduces hypoxia-inducible factor 1α-mediated extracellular vesicle production by endothelial cells. Nitric Oxide. 63:1–12. DOI: 10.1016/j.niox.2016.12.005. PMID: 28017872.

19. Min Lim K, Kim S, Yeom J, et al. 2023; Advanced 3D dynamic culture system with transforming growth factor-β3 enhances production of potent extracellular vesicles with modified protein cargoes via upregulation of TGF-β signaling. J Adv Res. 47:57–74. DOI: 10.1016/j.jare.2022.09.005. PMID: 36130685. PMCID: PMC10173176.

20. Song K, Dayem AA, Lee S, et al. 2022; Superior therapeutic activity of TGF-β-induced extracellular vesicles against interstitial cystitis. J Control Release. 348:924–937. DOI: 10.1016/j.jconrel.2022.06.045. PMID: 35772569.

21. Lim KM, Dayem AA, Choi Y, et al. 2021; High therapeutic and esthetic properties of extracellular vesicles produced from the stem cells and their spheroids cultured from ocular surgery-derived waste orbicularis oculi muscle tissues. Antioxi-dants (Basel). 10:1292. DOI: 10.3390/antiox10081292. PMID: 34439540. PMCID: PMC8389225.

22. van der Fits L, Mourits S, Voerman JS, et al. 2009; Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis. J Immunol. 182:5836–5845. DOI: 10.4049/jimmunol.0802999. PMID: 19380832.

23. Wang Y, Zeng D, Wei L, et al. 2024; Effects of emulsifiers on lipid metabolism and performance of yellow-feathered broi-lers. BMC Vet Res. 20:246. DOI: 10.1186/s12917-024-04095-8. PMID: 38849831. PMCID: PMC11157903.

24. Beutner KR, Tyring S. 1997; Human papillomavirus and human disease. Am J Med. 102(5A):9–15. DOI: 10.1016/S0002-9343(97)00178-2. PMID: 9217657.

25. Zhou X, Chen Y, Cui L, Shi Y, Guo C. 2022; Advances in the pathogenesis of psoriasis: from keratinocyte perspective. Cell Death Dis. 13:81. DOI: 10.1038/s41419-022-04523-3. PMID: 35075118. PMCID: PMC8786887.

26. Dazzi F, Krampera M. 2011; Mesenchymal stem cells and autoimmune diseases. Best Pract Res Clin Haematol. 24:49–57. DOI: 10.1016/j.beha.2011.01.002. PMID: 21396592.

27. Kim CH, Lim CY, Lee JH, Kim KC, Ahn JY, Lee EJ. 2018; Human embryonic stem cells-derived mesenchymal stem cells reduce the symptom of psoriasis in imiquimod-indu-ced skin model. Tissue Eng Regen Med. 16:93–102. DOI: 10.1007/s13770-018-0165-3. PMID: 30815354. PMCID: PMC6361099.

28. Imai Y, Yamahara K, Hamada A, Fujimori Y, Yamanishi K. 2019; Human amnion-derived mesenchymal stem cells ameliorate imiquimod-induced psoriasiform dermatitis in mice. J Dermatol. 46:276–278. DOI: 10.1111/1346-8138.14768. PMID: 30632187.

29. Shin L, Peterson DA. 2013; Human mesenchymal stem cell grafts enhance normal and impaired wound healing by recruiting existing endogenous tissue stem/progenitor cells. Stem Cells Transl Med. 2:33–42. DOI: 10.5966/sctm.2012-0041. PMID: 23283490. PMCID: PMC3659748.

30. Caponnetto F, Manini I, Skrap M, et al. 2017; Size-dependent cellular uptake of exosomes. Nanomedicine. 13:1011–1020. DOI: 10.1016/j.nano.2016.12.009. PMID: 27993726.

31. Litvinov IV, Bizet AA, Binamer Y, Jones DA, Sasseville D, Philip A. 2011; CD109 release from the cell surface in human keratinocytes regulates TGF-β receptor expression, TGF-β signalling and STAT3 activation: relevance to psoriasis. Exp Dermatol. 20:627–632. DOI: 10.1111/j.1600-0625.2011.01288.x. PMID: 21539622.

32. Jiang M, Sun Z, Dang E, et al. 2017; TGFβ/SMAD/microRNA-486-3p signaling axis mediates keratin 17 expression and keratinocyte hyperproliferation in psoriasis. J Invest Dermatol. 137:2177–2186. DOI: 10.1016/j.jid.2017.06.005. PMID: 28642156.

33. Henriet E, Abdallah F, Laurent Y, et al. 2022; Targeting TGF-β1/miR-21 pathway in keratinocytes reveals protective effects of silymarin on imiquimod-induced psoriasis mouse model. JID Innov. 3:100175. DOI: 10.1016/j.xjidi.2022.100175. PMID: 36968096. PMCID: PMC10034514.

34. Herman A, Herman AP. 2015; Essential oils and their constituents as skin penetration enhancer for transdermal drug delivery: a review. J Pharm Pharmacol. 67:473–485. DOI: 10.1111/jphp.12334. PMID: 25557808.

35. Lai RC, Tan SS, Teh BJ, et al. 2012; Proteolytic potential of the MSC exosome proteome: implications for an exosome-mediated delivery of therapeutic proteasome. Int J Prote-omics. 2012:971907. DOI: 10.1155/2012/971907. PMID: 22852084. PMCID: PMC3407643.

36. Facchin BM, Dos Reis GO, Vieira GN, et al. 2022; Inflammatory biomarkers on an LPS-induced RAW 264.7 cell model: a systematic review and meta-analysis. Inflamm Res. 71:741–758. DOI: 10.1007/s00011-022-01584-0. PMID: 35612604.

37. Cai Y, Xue F, Quan C, et al. 2019; A critical role of the IL-1β-IL-1R signaling pathway in skin inflammation and psoriasis pathogenesis. J Invest Dermatol. 139:146–156. DOI: 10.1016/j.jid.2018.07.025. PMID: 30120937. PMCID: PMC6392027.